SEB Global Chance/Risk C EUR |
| Performance History | 31-12-2019 |
| Growth of 1,000 (EUR) |
 | Fund | 7.1 | 9.2 | 13.5 | -14.1 | 22.0 |
| +/-Cat | 0.3 | -1.3 | 6.8 | -4.8 | 0.6 |
| +/-Idx | 2.7 | -6.8 | 9.6 | -7.8 | -0.8 |
| Category: Global Large-Cap Value Equity | ||||||
| Benchmarks: MSCI ACWI Value NR USD | ||||||
| Key Stats | ||
| NAV 17-01-2020 | EUR 1.69 | |
| Day Change | 0.89% | |
| Morningstar Category™ | Global Large-Cap Value Equity | |
| ISIN | LU0122113094 | |
| Fund Size (Mil) 17-01-2020 | EUR 267.67 | |
| Share Class Size (Mil) 17-01-2020 | EUR 224.52 | |
| Max Initial Charge | 1.00% | |
| Ongoing Charge 02-01-2020 | 1.56% | |
| Investment Objective: SEB Global Chance/Risk C EUR |
| The Sub-Fund may invest up to 100% of its assets in different transferable securities issued or guaranteed by any Member State of the EU, its local authorities, or public international bodies of which one or more of such Member States are members, or by any other State of the OECD. The Sub-Fund can only make use of this provision if it holds securities from at least six different issues, and if securities from any one issue may not account for more than 30% of the Sub - Fund’s total net assets. |
| Returns | |||||||||||||
|
| Management | ||
Manager Name Start Date | ||
Christian Darenhill 29-01-2013 | ||
Inception Date 08-01-2001 | ||
| Advertisement |
| Benchmarks | |
| Fund Benchmark | Morningstar Benchmark |
| MSCI ACWI NR EUR | MSCI ACWI Value NR USD |
| Target Market | ||||||||||||||||||||
| ||||||||||||||||||||
| Portfolio Profile for SEB Global Chance/Risk C EUR | 31-12-2019 |
| |||||||||||||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||
| Top 5 Holdings | Sector | % |
 Microsoft Corp |  Technology | 3.15 |
| Roche Holding AG Dividend Right ...
|  Healthcare | 2.17 |
| Bristol-Myers Squibb Company | Healthcare | 2.08 |
| Amgen Inc | Healthcare | 1.97 |
 Merck & Co Inc | Healthcare | 1.95 |
 | ||
Increase Decrease  New since last portfolio | ||
| SEB Global Chance/Risk C EUR | ||
